Investment Rating - The report maintains an investment rating of "Outperform" for the traditional Chinese medicine (TCM) sector, indicating a positive outlook compared to the broader market [5]. Core Insights - The retail sales of traditional Chinese medicine (TCM) in pharmacies are expected to experience slight pressure in 2025, with a year-on-year decline of 7.2%, attributed to stricter regulatory policies, a challenging macroeconomic environment, and operational pressures on retail pharmacies [14]. - The report highlights stable rankings among major products in various therapeutic areas, despite the overall sales decline [13]. Summary by Sections Overall Situation - The retail sales of TCM in pharmacies from 2017 to 2025 show a fluctuating upward trend with a compound annual growth rate (CAGR) of 1.0%. The total sales in 2025 are projected to be 155.9 billion yuan [14]. Cold and Flu Remedies - Sales of cold and flu TCM products are expected to fluctuate significantly, with a CAGR of 1.4%. In Q4 2025, sales are estimated at approximately 7.4 billion yuan, reflecting a 30.1% quarter-on-quarter increase due to a resurgence of respiratory infections [18]. Nutritional Supplements - The sales of nutritional supplements in TCM are relatively stable, with 2025 sales projected at 22.7 billion yuan. However, a slight decline is anticipated in 2024 and 2025 due to high sales in 2023 and a challenging consumption environment [21]. Cardiovascular Products - The cardiovascular TCM market has shown steady growth with a CAGR of 7.3% from 2017 to 2023. However, a decline in sales is expected in 2024 and 2025, primarily due to high sales in 2023 and regulatory pressures [24]. Musculoskeletal Products - Sales in the musculoskeletal TCM sector are projected to decrease from 19.8 billion yuan in 2017 to 14.8 billion yuan in 2025, influenced by significant declines in key products. Nonetheless, long-term growth potential exists due to an aging population [27]. Gastrointestinal Products - The gastrointestinal TCM market has shown stable demand, with sales increasing from 11.3 billion yuan in 2017 to 16.6 billion yuan in 2023. A slight decline is expected in 2024 and 2025, but long-term demand remains stable [30]. Cough and Phlegm Remedies - The cough and phlegm TCM market has experienced a CAGR of 2.0%, with significant sales increases in 2022 and 2023. However, a decline in sales is anticipated in 2024 and 2025, although levels will remain higher than pre-2021 figures [33].